Enhancing Week-long Psychological Treatment for PTSD With Ketamine

This interventional trial (n=162) aims to evaluate the efficacy of combining ketamine with trauma-focused psychotherapy for treating post-traumatic stress disorder (PTSD) over a week-long period.

Conducted by Yale University, this study seeks to determine whether ketamine, compared to midazolam, enhances the therapeutic effects of psychotherapy in alleviating PTSD symptoms. The treatment involves administering ketamine or midazolam infusions on days 2 and 4, alongside psychotherapy sessions from days 3 to 6. MRI scans will assess brain reactivity to PTSD before and after treatment. Participants will undergo follow-up evaluations at 30 and 90 days post-treatment.

The study aims to explore neurophysiological changes and assess amygdala activation, PTSD symptom severity, task-based connectivity, and psychophysiological distress to trauma reminders. Eligible participants must be between 21-70 years old, have a diagnosis of PTSD, and meet specific inclusion criteria. The trial commenced in August 2023 and is expected to conclude by August 2031.

Topic PTSD
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.